The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most malignant cells displayed weak to moderate cytoplasmic staining. A fraction of malignant gliomas showed additional nuclear staining.
Moderate to strong cytoplasmic positivity was observed in a majority of malignant cells. Malignant gliomas, lymphomas and melanomas as well as skin and testicular cancers were weakly stained or negative.
Several cases of prostate and hepatocellular carcinomas as well as a few cases of renal cancer showed moderate cytoplasmic positivity. Remaining malignancies were negative or weakly stained.
Malignant lymphomas showed moderate to strong cytoplasmic staining. Several cases of colorectal, prostate, renal and liver cancers showed moderate positivity. Remaining malignancies were weakly stained or negative.
tissues exhibited weak cytoplasmic immunoreactivity or were negative. Non-Hodgkins lymphomas expressed moderate to strong cytoplasmic staining. Cases of malignant carcinoids, colorectal, prostate, liver and renal cancers showed moderate positivity.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
Two (or more) antibodies yielding partly similar staining patterns which are consistent with gene/protein characterization data
